Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 5/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43576 | 0.90 | PSMB8 (0.35) | PSMB8PSMB5LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL10071372 | 0.89 | SMN1; SMN2 (0.38) | ALDH1A1PSMB8PSMB5KMT2ASMN1; SMN2 | |
| SCHEMBL829438 | 0.89 | SMN1; SMN2 (0.35) | ALDH1A1PSMB8PSMB5GLAKMT2A | |
| SCHEMBL16575143 | 0.88 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL31522720 | 0.88 | PSMB8 (0.34) | PSMB8PSMB5LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL469600 | 0.87 | SMN1; SMN2 (0.40) | ALDH1A1PSMB8PSMB5KMT2ASMN1; SMN2 | |
| SCHEMBL10071373 | 0.87 | SMN1; SMN2 (0.40) | ALDH1A1PSMB8PSMB5KMT2ASMN1; SMN2 | |
| SCHEMBL12896267 | 0.87 | SMN1; SMN2 (0.40) | ALDH1A1PSMB8PSMB5KMT2ASMN1; SMN2 | |
| SCHEMBL28381750 | 0.85 | PSMB8 (0.33) | PSMB8PSMB5GLAKMT2ASMN1; SMN2 | |
| SCHEMBL2454952 | 0.85 | TSHR (0.50) | ALDH1A1PSMB8PSMB5LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101052617-B | Process for the preparation of alkyl 5-(dicarboximido)levulinate and alkyl 4-oxo-pentenoate | BIOSYNTH AB | 2010-11-03 | — | — | CN | claimed |
| CN-101052617-A | Process for the preparation of alkyl 5-(dicarboximido)levulinate and alkyl 4-oxo-pentenoate | BIOSYNTH AB (SE) | 2007-10-10 | — | — | CN | claimed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-2911699-B2 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2025-09-10 | — | — | EP | disclosed |
| US-20250177554-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX B.V. (NL) | 2025-06-05 | — | — | US | disclosed |
| US-12194107-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | SYNAFFIX B.V. (NL) | 2025-01-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | GLYKOS FINLAND OY (FI) | 2023-08-15 | — | — | US | disclosed |
| EP-3912642-B1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2023-04-12 | — | — | EP | disclosed |
| EP-1351991-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | Schwartz, David A. (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | AUDAX PRIVATE DEBT LLC, AS AGENT | 2002-10-10 | — | — | US | disclosed |
| EP-1235851-A2 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | Johns Hopkins University School of Medicine (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001027135-A9 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | UNIV JOHNS HOPKINS MED (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002057422-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010431-A2 | FUNCTIONAL BIOPOLYMER MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001027135-A2 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | FUT6, CD44, SIGLEC7 | ALDH1A1 1521/4885PSMB8 1376/4885PSMB5 1592/4885 |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | EPCAM, DNPEP, ANPEP | ALDH1A1 552/4885PSMB8 2758/4885PSMB5 1281/4885 |
| US-12194107-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | FUT5, FUT6, FUT4 | ALDH1A1 927/4885PSMB8 1399/4885PSMB5 307/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | ALDH1A1 3438/4885PSMB8 1093/4885PSMB5 1619/4885 |
| US-20250177554-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | FUT5, FUT6, FUT4 | ALDH1A1 927/4885PSMB8 1399/4885PSMB5 307/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | ALDH1A1 3684/4885PSMB8 1004/4885PSMB5 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.